Detailed Notes on Dup 747
Contraindicated (one)bortezomib will raise the degree or result of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or reasonable CYP2C19 inhibitors could enhance mavacamten systemic exposure, causing heart failure resulting from systolic dysfunction.To lower the potential risk of dizziness and lightheadedness, stan